Surgical Science Sweden AB (publ)

OM:SUS Stock Report

Market Cap: SEK 7.3b

Surgical Science Sweden Valuation

Is SUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SUS (SEK142.5) is trading below our estimate of fair value (SEK318.4)

Significantly Below Fair Value: SUS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SUS?

Key metric: As SUS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SUS. This is calculated by dividing SUS's market cap by their current earnings.
What is SUS's PE Ratio?
PE Ratio37.6x
EarningsSEK 193.34m
Market CapSEK 7.27b

Price to Earnings Ratio vs Peers

How does SUS's PE Ratio compare to its peers?

The above table shows the PE ratio for SUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average48.9x
ELOS B Elos Medtech
104.3xn/aSEK 5.7b
CEVI CellaVision
35.7x22.8%SEK 5.4b
ARJO B Arjo
18.3x24.5%SEK 9.2b
STIL Stille
37.1x36.8%SEK 1.9b
SUS Surgical Science Sweden
37.6x36.1%SEK 7.3b

Price-To-Earnings vs Peers: SUS is good value based on its Price-To-Earnings Ratio (37.6x) compared to the peer average (48.9x).

Price to Earnings Ratio vs Industry

How does SUS's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SUS 37.6xIndustry Avg. 29.7xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SUS is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is SUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SUS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.6x
Fair PE Ratio38.5x

Price-To-Earnings vs Fair Ratio: SUS is good value based on its Price-To-Earnings Ratio (37.6x) compared to the estimated Fair Price-To-Earnings Ratio (38.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SUS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 142.50
SEK 192.17
+34.9%
10.0%SEK 225.00SEK 165.00n/a6
Nov ’25SEK 127.90
SEK 188.17
+47.1%
15.3%SEK 225.00SEK 135.00n/a6
Oct ’25SEK 122.90
SEK 188.17
+53.1%
15.3%SEK 225.00SEK 135.00n/a6
Sep ’25SEK 124.00
SEK 189.00
+52.4%
14.4%SEK 225.00SEK 140.00n/a6
Aug ’25SEK 127.90
SEK 204.00
+59.5%
19.1%SEK 260.00SEK 140.00n/a6
Jul ’25SEK 125.00
SEK 204.00
+63.2%
19.1%SEK 260.00SEK 140.00n/a6
Jun ’25SEK 144.60
SEK 208.17
+44.0%
15.7%SEK 260.00SEK 165.00n/a6
May ’25SEK 157.10
SEK 221.50
+41.0%
13.6%SEK 260.00SEK 165.00n/a6
Apr ’25SEK 151.70
SEK 222.33
+46.6%
13.7%SEK 260.00SEK 165.00n/a6
Mar ’25SEK 155.20
SEK 228.17
+47.0%
9.1%SEK 260.00SEK 200.00n/a6
Feb ’25SEK 179.30
SEK 239.00
+33.3%
11.1%SEK 275.00SEK 200.00n/a6
Jan ’25SEK 182.50
SEK 236.50
+29.6%
13.8%SEK 275.00SEK 180.00n/a6
Dec ’24SEK 175.50
SEK 236.50
+34.8%
13.8%SEK 275.00SEK 180.00n/a6
Nov ’24SEK 129.00
SEK 242.33
+87.9%
12.0%SEK 280.00SEK 195.00SEK 127.906
Oct ’24SEK 150.30
SEK 254.00
+69.0%
14.4%SEK 300.00SEK 195.00SEK 122.905
Sep ’24SEK 164.20
SEK 263.00
+60.2%
9.3%SEK 300.00SEK 235.00SEK 124.005
Aug ’24SEK 237.00
SEK 272.20
+14.9%
10.9%SEK 300.00SEK 233.00SEK 127.905
Jul ’24SEK 241.20
SEK 272.20
+12.9%
10.9%SEK 300.00SEK 233.00SEK 125.005
Jun ’24SEK 230.00
SEK 272.20
+18.3%
10.9%SEK 300.00SEK 233.00SEK 144.605
May ’24SEK 187.10
SEK 233.40
+24.7%
18.6%SEK 290.00SEK 182.00SEK 157.105
Apr ’24SEK 169.20
SEK 232.40
+37.4%
18.9%SEK 290.00SEK 182.00SEK 151.705
Mar ’24SEK 172.10
SEK 236.00
+37.1%
21.4%SEK 290.00SEK 170.00SEK 155.204
Feb ’24SEK 148.70
SEK 239.00
+60.7%
23.1%SEK 305.00SEK 170.00SEK 179.304
Jan ’24SEK 164.70
SEK 239.00
+45.1%
23.1%SEK 305.00SEK 170.00SEK 182.504
Dec ’23SEK 148.40
SEK 262.00
+76.5%
16.9%SEK 305.00SEK 201.00SEK 175.503
Nov ’23SEK 160.80
SEK 273.00
+69.8%
17.2%SEK 320.00SEK 209.00SEK 129.003

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Iconovo

SEK 78.6m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.10

7D

-1.2%

1Y

-46.3%

Dignitana

SEK 92.6m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.10

7D

-4.3%

1Y

-48.6%

Mentice

SEK 544.6m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 21.00

7D

-16.0%

1Y

-52.3%